Journal
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
Volume 14, Issue 7, Pages 825-836Publisher
HARBORSIDE PRESS
DOI: 10.6004/jnccn.2016.0087
Keywords
-
Categories
Funding
- AstraZeneca
- Bayer Healthcare Pharmaceuticals Inc.
- Bristol-Myers Squibb
- Clovis Oncology
- Foundation Medicine
- Genentech
- Novartis Oncology
- Otsuka America Pharmaceutical, Inc.
- Seattle Genetics, Inc.
- Takeda Oncology
- Actelion Pharmaceuticals US, Inc.
- Astellas
- Medivation, Inc.
Ask authors/readers for more resources
These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for Malignant Pleural Mesothelioma (MPM). These NCCN Guidelines Insights discuss systemic therapy regimens and surgical controversies for MPM. The NCCN panel recommends cisplatin/pemetrexed (category1) for patients with MPM. The NCCN panel also now recommends bevacizumab/cisplatin/pemetrexed as a first-line therapy option for patients with unresectable MPM who are candidates for bevacizumab. The complete version of the NCCN Guidelines for MPM, available at NCCN. org, addresses all aspects of management for MPM including diagnosis, evaluation, staging, treatment, surveillance, and therapy for recurrence and metastasis; NCCN Guidelines are intended to assist with clinical decision-making.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available